Generic placeholder image

Current Medicinal Chemistry


ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology

Author(s): Kresimir Kostovic*, Sandra J. Gulin, Zrinka B. Mokos and Romana Ceovic

Volume 24, Issue 11, 2017

Page: [1158 - 1167] Pages: 10

DOI: 10.2174/1874467210666170113104503

Price: $65


Background: Tofacitinib (formerly known as CP-690,550, CP690550, tasocitinib), a novel selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The aim of this review article is to present updated data summary on the tofacitinib in the field of dermatology.

Method: We undertook a structured search of bibliographic databases for peer-reviewed scientific articles, including review articles, original research articles as well as case report articles based on inclusion/exclusion criteria. Technical reports on tofacitinib from U.S. Food and Drug Administration and European Medical Agency were also included.

Results: Forty-three papers were included in this review. We report current data on tofacitinib chemical properties, pharmacology, non-clinical toxicity, as well as efficacy and safety in potential new indications in dermatology: psoriasis, alopecia areata, vitiligo, atopic dermatitis and nail dystrophy associated with alopecia areata.

Conclusion: JAK/STAT pathway has an important role in the pathogenesis of psoriasis, alopecia areata, atopic dermatitis, and vitiligo. Despite encouraging efficacy, due to concerns about the overall safety profile of tofacitinib, additional studies will have to determine the adequate risk-to-benefit ratio.

Keywords: Tofacitinib, CP690550, protein kinase inhibitor, JAK/STAT pathway, small molecule, psoriasis, alopecia areata, vitiligo.

« Previous

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy